Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | PREP | P48147 | 4/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519326 | 0.88 | CA12 (0.46) | CA12CA1CA9PREPHTT | |
| SCHEMBL20046200 | 0.85 | CA1 (0.43) | CA12CA1CA9PREPHTT | |
| SCHEMBL3866565 | 0.83 | HTT (0.44) | RXRBRXRAHTTALDH1A1KDM4E | |
| SCHEMBL1656366 | 0.82 | CA12 (0.43) | CA12CA1CA9ALDH1A1KDM4E | |
| SCHEMBL7308992 | 0.82 | CA12 (0.43) | CA12CA1CA9PREPALDH1A1 | |
| SCHEMBL1604135 | 0.82 | CA12 (0.43) | CA12CA1CA9PREPALDH1A1 | |
| SCHEMBL29053391 | 0.81 | CA12 (0.46) | CA12CA1CA9PREPALDH1A1 | |
| SCHEMBL5509632 | 0.81 | CA12 (0.43) | CA12CA1CA9PREPALDH1A1 | |
| SCHEMBL28613347 | 0.81 | CA12 (0.43) | CA12CA1CA9PREPALDH1A1 | |
| SCHEMBL9097136 | 0.80 | CA12 (0.44) | CA12CA1CA9PREPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008157330-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1848463-A2 | METHOD OF CONJUGATING AMINOTHIOL CONTAINING MOLECULES TO VEHICLES | Amgen Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060199812-A1 | Method of conjugating aminothiol containing molecules to vehicles | AMGEN INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006079099-A2 | METHOD OF CONJUGATING AMINOTHIOL CONTAINING MOLECULES TO A POLYMER | AMGEN INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199812-A1 | Method of conjugating aminothiol containing molecules to vehicles | SLC7A1, QPCT, SLC7A5 | CA12 1890/4885CA1 2857/4885CA9 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.